Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
NCT07509151 · SOUNDTRACK-C1 Phase 3Recruiting
- Lead sponsor
- AstraZeneca (Industry)
- Enrollment
- 420 (estimated)
- Start date
- 5 May 2026
- Primary completion
- 29 Aug 2031 (estimated)
- Study completion
- 5 Apr 2032
- Last update posted
- 6 Oct 2026
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Randomized
- Intervention model
- Sequential
- Masking
- None
- Arms
- 4
Interventions
- Surovatamig Drug
Conditions and primary outcome
- Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated IGHV
Primary outcome
DOSRI- Number of participants with adverse events (AEs) and Serious Adverse Events (SAEs) (Up to 5 years); Phase III- Progression Free Survival (PFS) (Until disease progression or death (up to 5 years)); DOSRI- Number of participants with study intervention discontinuations, dose reductions and dose delays due to AEs (Up to 5 years)
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
No PubMed citation lists NCT07509151.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT07509151 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.